ArticleVaccines2021

Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2.

Jorge Hernández-Bello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.